The UK Biobank data exposure highlights a growing risk in modern health research: sensitive data is not only vulnerable to breaches, but to systemic leakage through normal scientific practices. This raises urgent...read more
Category - Next generation sequencing
Tempus Scoops Up OneOme’s Pharmacogenetics Assets as Precision Medicine Shakeout Continues
Tempus AI has acquired the pharmacogenetics assets of OneOme, a once-promising precision medicine startup that abruptly shut down earlier this year amid financial troubles. The deal marks the latest in a flurry of...read more
Tempus Announces the Acquisition of Paige
Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ: TEM), a technology company leading...read more
The Critical Link Between CROs and Sponsors: Making Data Work for You
Maximizing Focus, Minimizing Cost: The Strategic Logic of CRO Engagement Outsourcing to Contract Research Organizations (CROs) has been a fundamental practice in therapeutic and device discovery and early development...read more
